Literature DB >> 34264157

Comparing different CT, PET and MRI multi-modality image combinations for deep learning-based head and neck tumor segmentation.

Jintao Ren1,2,3, Jesper Grau Eriksen1,4, Jasper Nijkamp1,2, Stine Sofia Korreman1,2,3.   

Abstract

BACKGROUND: Manual delineation of gross tumor volume (GTV) is essential for radiotherapy treatment planning, but it is time-consuming and suffers inter-observer variability (IOV). In clinics, CT, PET, and MRI are used to inform delineation accuracy due to their different complementary characteristics. This study aimed to investigate deep learning to assist GTV delineation in head and neck squamous cell carcinoma (HNSCC) by comparing various modality combinations.
MATERIALS AND METHODS: This retrospective study had 153 patients with multiple sites of HNSCC including their planning CT, PET, and MRI (T1-weighted and T2-weighted). Clinical delineations of gross tumor volume (GTV-T) and involved lymph nodes (GTV-N) were collected as the ground truth. The dataset was randomly divided into 92 patients for training, 31 for validation, and 30 for testing. We applied a residual 3 D UNet as the deep learning architecture. We independently trained the UNet with four different modality combinations (CT-PET-MRI, CT-MRI, CT-PET, and PET-MRI). Additionally, analogical to post-processing, an average fusion of three bi-modality combinations (CT-PET, CT-MRI, and PET-MRI) was produced as an ensemble. Segmentation accuracy was evaluated on the test set, using Dice similarity coefficient (Dice), Hausdorff Distance 95 percentile (HD95), and Mean Surface Distance (MSD).
RESULTS: All imaging combinations including PET provided similar average scores in range of Dice: 0.72-0.74, HD95: 8.8-9.5 mm, MSD: 2.6-2.8 mm. Only CT-MRI had a lower score with Dice: 0.58, HD95: 12.9 mm, MSD: 3.7 mm. The average of three bi-modality combinations reached Dice: 0.74, HD95: 7.9 mm, MSD: 2.4 mm.
CONCLUSION: Multimodal deep learning-based auto segmentation of HNSCC GTV was demonstrated and inclusion of the PET image was shown to be crucial. Training on combined MRI, PET, and CT data provided limited improvements over CT-PET and PET-MRI. However, when combining three bimodal trained networks into an ensemble, promising improvements were shown.

Entities:  

Keywords:  CNN; Deep learning; GTV; UNet; auto-segmentation; head and neck cancer

Mesh:

Year:  2021        PMID: 34264157     DOI: 10.1080/0284186X.2021.1949034

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

1.  Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial.

Authors:  Thomas Held; Thomas Tessonnier; Henrik Franke; Sebastian Regnery; Lukas Bauer; Katharina Weusthof; Semi Harrabi; Klaus Herfarth; Andrea Mairani; Jürgen Debus; Sebastian Adeberg
Journal:  Radiat Oncol       Date:  2022-07-08       Impact factor: 4.309

2.  Evaluation of deep learning-based multiparametric MRI oropharyngeal primary tumor auto-segmentation and investigation of input channel effects: Results from a prospective imaging registry.

Authors:  Kareem A Wahid; Sara Ahmed; Renjie He; Lisanne V van Dijk; Jonas Teuwen; Brigid A McDonald; Vivian Salama; Abdallah S R Mohamed; Travis Salzillo; Cem Dede; Nicolette Taku; Stephen Y Lai; Clifton D Fuller; Mohamed A Naser
Journal:  Clin Transl Radiat Oncol       Date:  2021-10-16

3.  Challenges and chances for deep-learning based target and organ at risk segmentation in radiotherapy of head and neck cancer.

Authors:  Jasper Nijkamp
Journal:  Phys Imaging Radiat Oncol       Date:  2022-08-11

4.  Strategies for tackling the class imbalance problem of oropharyngeal primary tumor segmentation on magnetic resonance imaging.

Authors:  Roque Rodríguez Outeiral; Paula Bos; Hedda J van der Hulst; Abrahim Al-Mamgani; Bas Jasperse; Rita Simões; Uulke A van der Heide
Journal:  Phys Imaging Radiat Oncol       Date:  2022-08-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.